Structural and Physical Basis for Anti-IgE Therapy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wright, Jon D ^a,b   Chu, Hsing Mao ^b   Huang, Chun Hsiang ^b   Ma, Che ^b   Wen Chang, Tse ^b   Lim, Carmay ^a,c  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-IGE ANTIBODIES; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; OMALIZUMAB; PROTEIN BINDING;

AMINO ACID SEQUENCE; ASTHMA; BINDING SITE; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR MODEL; MUTATION; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ASTHMA; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNOGLOBULIN E; MODELS, MOLECULAR; MUTATION; OMALIZUMAB; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, IGE;

EID: 84933074093     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11581     Document Type: Article

References (54)

1. Gould, H. J. & Sutton, B. J. IgE in allergy and asthma today. Nat. Rev. Immunol. 8, 205-217 (2008).
2. Chang, T. W. et al. Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases. Bio/technology 8, 122-126 (1990).
3. Brightbill, H. D. et al. Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J. Clin. Invest. 120, 2218-2229 (2010).
4. Saini, S. et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J. Allergy Clin. Immunol. 128, 567-573 (2011).
5. Maurer, M. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 368, 924-935 (2013).
6. Chang, T. W. et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J. Allergy Clin. Immunol. 135, 337-342 (2015).
7. Bialy H. Can antibodies to IgE act as anti-allergics? Nature Biotech. 8, 96 (1990)
8. Saini, S. S. et al. Down-regulation of Fc? RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. 158, 1438-1445 (1997).
9. Beck, L. A., Marcotte, G. V., MacGlashan, D., Togias, A. & Saini, S. Omalizumab-induced reductions in mast cell Fc? RI expression and function. J. Allergy Clin. Immunol. 114, 527-530 (2004).
10. Prussin, C. et al. Omalizumab treatment downregulates dendritic cell Fc? RI expression. J. Allergy Clin. Immunol. 112, 1147-1154, (2003).
11. Davis, F. M. et al. Can anti-IgE be used to treat allergy? Springer Semin. Immunopathol. 15, 51-73 (1993).
12. Chang, T. W., Wu, P. C., Hsu, C. L. & Hung, A. F. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Advances in Immunol. 93, 63-119 (2007).
13. Wright, J. D. & Lim, C. Prediction of an anti-IgE binding site on IgE. Prot. Eng. 11, 421-427 (1998).
14. Presta, L. G. & Shields, R. L. IgE and Anti-IgE Therapy in Asthma and Allergic Disease. Vol. 164 23-38 (Marcel Dekker 2002).
15. Garman, S. C., Wurzburg, B. A., Tarchevskaya, S. S., Kinet, J. P. & Jardetzky, T. S. Structure of the Fc fragment of human IgE bound to its high affinity receptor Fc? RI? . Nature 406, 259-266 (2000).
16. Holdom, M. D. et al. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor Fc? RI. Nat. Struct. Mol. Biol. 18, 571-576 (2011).
17. Dhaliwal, B. et al. Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor Fc? RI. Proc. Natl. Acad. Sci. USA 109, 12686-12691 (2012).
18. Yuan, D. et al. Ca2+-dependent structural changes in the B-cell receptor CD23 increase its affinity for human immunoglobulin E. J. Biol. Chem. 288, 21667-21677 (2013).
19. Cohen, E. S. et al. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. mAbs 6, 755-763 (2014).
20. Drinkwater, N. et al. Human immunoglobulin E flexes between acutely bent and extended conformations. Nat. Struct. Mol. Biol. 21, 397-404 (2014).
21. Wurzburg, B. A. et al. An engineered disulfide bond reversibly traps the IgE-Fc 3-4 in a closed, nonreceptor binding conformation. J. Biol. Chem. 287, 36251-36257 (2012).
22. Hunt, J. et al. A fluorescent biosensor reveals conformational changes in human immunoglobulin E Fc: implications for mechanisms of receptor binding, inhibition, and allergen recognition. J. Biol. Chem. 287, 17459-17470 (2012).
23. Wright, J. D., Sargsyan, K., Wu, X., Brooks, B. R. & Lim, C. Protein-protein docking using EMAP in CHARMM and support vector machine: Application to Ab/Ag complexes J. Chem. Theory & Comput. 9, 4186-4194 (2013).
24. Wu, Y. Y. & Kabat, E. A. An analysis of the sequences of the variable regions of Bence-Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med 132, 211-249 (1970).
25. Baker, N. A., Sept, D., Joseph, S., Holst, M. J. & McCammon, J. A. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. USA 98, 10037-10041 (2001).
26. Presta, L. G. et al. Humanization of an antibody directed against IgE. J. Immunol. 151, 2623-2632 (1993).
27. Word, J. M., Lovell, S. C., Richardson, J. S. & Rchardson, D. C. Asparagine and glutamine: Using hydrogen atom contacts in the choice of side-chain amide orientation. J. Mol. Biol. 285, 1735-1747 (1999).
28. Vriend, G. WHAT IF: A molecular modeling and drug design program. J. Mol. Graph. 8, 52-56 (1990).
29. Dolinsky, T. J., Nielsen, J. E., McCammon, J. A. & Baker, N. A. PDB2PQR: an automated pipeline for the setup, execution, and analysis of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665-667 (2004).
30. Olsson, M. H. M., Søndergard, C. R., Rostkowski, M. R. & Jensen, J. H. PROPKA3: Consistent treatment of internal and surface residues in empirical pKa predictions. J. Chem. Theory & Comput. 7, 526-537 (2011).
31. Li, Y., Roy, A. & Zhang, Y. HAAD: A quick algorithm for accurate prediction of hydrogen atoms in protein structures. PLoS One 4, e6701 (2009).
32. Zheng, L. et al. Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab. Biochem. Biophys. Res. Commun. 375, 619-622 (2008).
33. Liu, J., Lester, P., Builder, S. & Shire, S. J. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34, 10474-10482 (1995).
34. Hwang, H., Pierce, B., Mintseris, J., Janin, J. & Weng, Z. Protein-protein docking benchmark version 3.0. Proteins: Struct. Funct. & Bioinf. 73, 705-709 (2008).
35. Woo, H.-J. & Roux, B. Calculation of absolute protein-ligand binding free energy from computer simulations. Proc. Natl. Acad. Sci. U.S.A 102, 6825-6830 (2005).
36. Zheng, Y., Shopes, B., Holowka, D. & Baird, B. Conformations of IgE bound to its receptor FceRI and in solution. Biochemistry 30, 9125-9132 (1991).
37. Beavil, A. J., Young, R. J., Sutton, B. J. & Perkins, S. J. Bent domain structure of recombinant human IgE-Fc in solution by X-ray and neutron scattering in conjunction with an automated curve fitting procedure. Biochemistry 34, 14449-14461 (1995).
38. Wan, T. et al. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat. Immunol. 3, 681-686 (2002).
39. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Method Enzymol. 276, 307-326 (1997).
40. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
41. Uysal, H. et al. The crystal structure of the pathogenic collagen type II-specific mouse monoclonal antibody CIIC1 Fab: structure to function analysis. Mol. Immunol. 45, 2196-2204 (2008).
42. Adams P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Cryst. D66, 213-221 (2010)
43. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D-Biol. Crystallogr. 66, 486-501 (2010).
44. Brooks, B. R. et al. CHARMm: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4, 187-217 (1983).
45. Reiher, W. E. Theoretical Studies of Hydrogen Bonding PhD thesis, Harvard University (1985).
46. Wu, X.-W. et al. A core-weighted fitting method for docking atomic structures into low resolution maps: Application to cyroelectron microsopy. J. Struct. Biol. 141, 63-69 (2003).
47. Mendez, R., Leplae, R., Lensink, M. F. & Wodak, S. J. Assessment of CAPRI predictions in rounds 3-5 shows progress in docking procedures. Proteins 60, 150-169 (2005).
48. Vanommeslaeghe, K. et al. CHARMM general force field (CGenFF): A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comp. Chem. 31, 671-690 (2010).
49. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935 (1983).
50. Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N.log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089-10092 (1993).
51. Srinivasan, J., III, T. E. C., Cieplak, P., Kolman, P. A. & Case, D. A. Continuum solvent studies of the stability of DNA, RNA and phosphoramidate-DNA Helices. J. Am. Chem. Soc. 120, 9401-9409 (1998).
52. Lo, C.-H. et al. A combined experimental and theoretical study of long-range interactions modulating dimerization and activity of yeast geranylgeranyl diphosphate synthase. J. Am. Chem. Soc. 131, 4051-4062 (2009).
53. Wang, Y. T. et al. Redesign of a non-specific endonuclease to yield better DNA-binding activity and altered DNA sequence preference in cleavage. J. Am. Chem. Soc. 131, 17345-17353 (2009).
54. Im, W., Beglov, D. Continuum solvation model: Computation of electrostatic forces from numerical solutions to the Poisson-Boltzmann equation. Comput. Phys. Commun. 111, 59-75 (1998).